James C. Robinson

St David's Medical Center — United States

Economics, Econometrics and Finance · Social Sciences

52h-index8.9kcitations278works6.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Healthcare Policy and Management(112), Health Systems, Economic Evaluations, Quality of Life(70), Primary Care and Health Outcomes(48), Pharmaceutical Economics and Policy(47), Global Health Care Issues(23)

Publications277 total

In (Faint) Praise of Pharmaceutical Import Tariffs
JAMA·2025
Hospital Prices for Physician-Administered Drugs
New England Journal of Medicine·2024· 1 cited
Prices and Complications in Hospital-Based and Freestanding Surgery Centers
The American Journal of Managed Care·2024· 8 cited
Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance
New England Journal of Medicine·2024· 18 cited
How Industrial Policy Could Accelerate Innovation In The Life Sciences
Health Affairs·2023· 5 cited
<b>Pharmacy Benefit Management:</b> The Cost of Drug Price Rebates
The Journal of Law Medicine & Ethics·2023
Germany’s Use Of Reference Pricing For Biologics: Lessons For The US
Health Affairs·2022· 3 cited
An Innovation Surcharge to Fund the Repurposing of Generic Drugs
JAMA·2022· 4 cited
Pricing of Drugs With Evidence Development—Reply
JAMA·2022
Drug Pricing With Evidence Development
JAMA·2022· 9 cited
Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals
Therapies·2021· 13 cited
Harmonization Of Health Technology Assessment Across The European Union: Lessons For The United States
Forefront Group·2021· 2 cited
Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform
New England Journal of Medicine·2021· 13 cited
Competing With, And Learning From, China In The Global Pharmaceutical Innovation Race
Forefront Group·2021
Drug Pricing, Competition, And Regulation: The Authors Reply
Health Affairs·2021
The Role Of Utilization Management: The Authors Reply
Health Affairs·2021
Price Differences To Insurers For Infused Cancer Drugs In Hospital Outpatient Departments And Physician Offices
Health Affairs·2021· 15 cited
Competition From Biosimilars Drives Price Reductions For Biologics In The French Single-Payer Health System
Health Affairs·2021· 22 cited
Quantifying The Economic Burden Of Drug Utilization Management On Payers, Manufacturers, Physicians, And Patients
Health Affairs·2021· 39 cited
Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic
JAMA·2021· 29 cited
page 1 of 14Next →

Frequent Co-authors

Lawrence P. Casalino(7), Stephen M. Shortell(5), Robin R. Gillies(4), Donald L. Budenz(4), William J. Feuer(4), Thomas G. Rundall(3), Harold S. Luft(3), Deborah W. Garnick(3), Keith Barton(3), Joyce Schiffman(3), Andreas Albrecht(3), Richard A. Battye(3), Thomas Bodenheimer(2), Nancy Oswald(2), Margaret C. Wang(2), Vital Paulino Costa(2), David G. Godfrey(2), Yvonne M. Buys(2), Stephen J. McPhee(2), Ciaran S. Phibbs(2)